Evaluation of Strategic Alternatives is Ongoing
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its third quarter ended March 31, 2025.
As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company is considering options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company’s exclusive financial advisor in this process.
Through the third quarter of fiscal year 2025, the Company’s cash preservation efforts continue and include a reduction-in-force progressing in stages as the Company’s operational and strategic direction evolves.
There can be no assurance the exploration of strategic alternatives will result in any agreements or transactions, or, if completed, any agreements or transactions will be successful or on attractive terms. The Company does not expect to disclose developments with respect to this process unless or until the evaluation of strategic alternatives has been completed or the Board of Directors has concluded disclosure is appropriate or legally required.
As of March 31, 2025, the Company had $20.5 million in cash and cash equivalents with no outstanding debt.
About MEI Pharma
MEI Pharma, Inc. (Nasdaq: MEIP) is a pharmaceutical company with a portfolio of several drug candidates that may offer novel and differentiated cancer therapies. The drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 inhibitor. For more information, please visit www.meipharma.com. Follow us on X (formerly Twitter) @MEI_Pharma and on LinkedIn.
Forward-Looking Statements
Certain information contained in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding the Company’s ability to identify, assess and execute a strategic transaction or realize value from its existing assets, the Company’s ability to preserve cash in order to adequately fund an orderly wind down of its operations if no transaction is consummated, the ability of stockholders and other stakeholders to realize any value or recovery as part of a transaction or a wind down process, the Company’s workforce reduction and future charges expected to be incurred in connection therewith, the adequacy or sufficiency of the Company’s existing cash resources and other statements. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, the Company’s ability to identify attractive strategic alternatives; the Company’s ability to retain key personnel; the adequacy of the Company’s capital resources in light of changing circumstances; the actions of various stakeholders of the Company; uncertainty regarding the impact of rising inflation , interest rates and tariffs; a potential economic downturn; activist investors; government regulation; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.
| Condensed Consolidated Balance Sheets | |||||||
| (in thousands, except par value amounts) | |||||||
|
|||||||
| March 31, 2025 |
June 30, 2024 |
||||||
| (Unaudited) | (Audited) | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ |
20,472 |
|
$ |
3,705 |
|
|
| Short-term investments |
|
— |
|
|
34,640 |
|
|
| Prepaid expenses and other current assets |
|
307 |
|
|
2,424 |
|
|
| Total current assets |
|
20,779 |
|
|
40,769 |
|
|
| Operating lease right-of-use asset |
|
— |
|
|
214 |
|
|
| Property and equipment, net |
|
— |
|
|
392 |
|
|
| Total assets | $ |
20,779 |
|
$ |
41,375 |
|
|
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ |
177 |
|
$ |
3,168 |
|
|
| Accrued liabilities |
|
1,061 |
|
|
5,187 |
|
|
| Total current liabilities |
|
1,238 |
|
|
8,355 |
|
|
| Total liabilities |
|
1,238 |
|
|
8,355 |
|
|
| Commitments and contingencies | |||||||
| Stockholders’ equity: | |||||||
| Preferred stock, $0.01 par value; 100 shares authorized; none outstanding |
|
— |
|
|
— |
|
|
| Common stock, $0.00000002 par value; 226,000 shares authorized; 6,663 shares issued and outstanding at March 31, 2025 and June 30, 2024 |
|
— |
|
|
— |
|
|
| Additional paid-in capital |
|
421,017 |
|
|
421,239 |
|
|
| Accumulated deficit |
|
(401,476 |
) |
|
(388,219 |
) |
|
| Total stockholders’ equity |
|
19,541 |
|
|
33,020 |
|
|
| Total liabilities and stockholders’ equity | $ |
20,779 |
|
$ |
41,375 |
|
|
| MEI Pharma, Inc. | |||||||||||||||
| Condensed Consolidated Statements of Operations | |||||||||||||||
| (Unaudited) | |||||||||||||||
| (in thousands, except per share amounts) | |||||||||||||||
|
|||||||||||||||
| Three Months Ended March 31, |
Nine Months Ended March 31, |
||||||||||||||
2025 |
2024 |
2025 |
2024 |
||||||||||||
| Total revenues | $ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
65,297 |
|
|||
| Operating expenses: | |||||||||||||||
| Research and development |
|
369 |
|
|
5,220 |
|
|
3,840 |
|
|
12,617 |
|
|||
| General and administrative |
|
2,405 |
|
|
4,609 |
|
|
10,737 |
|
|
19,158 |
|
|||
| Total operating expenses |
|
2,774 |
|
|
9,829 |
|
|
14,577 |
|
|
31,775 |
|
|||
| (Loss) income from operations |
|
(2,774 |
) |
|
(9,829 |
) |
|
(14,577 |
) |
|
33,522 |
|
|||
| Other income (expense): | |||||||||||||||
| Interest and dividend income |
|
202 |
|
|
706 |
|
|
836 |
|
|
2,669 |
|
|||
| Gain on disposition of a non-financial asset |
|
— |
|
|
— |
|
|
500 |
|
|
— |
|
|||
| Other expense, net |
|
(1 |
) |
|
(4 |
) |
|
(16 |
) |
|
(7 |
) |
|||
| Net (loss) income | $ |
(2,573 |
) |
$ |
(9,127 |
) |
$ |
(13,257 |
) |
$ |
36,184 |
|
|||
| Net (loss) income per share - basic and diluted | $ |
(0.39 |
) |
$ |
(1.37 |
) |
$ |
(1.99 |
) |
$ |
5.43 |
|
|||
| Weighted-average shares used in computing net (loss) income per share - basic and diluted: |
|
6,663 |
|
|
6,663 |
|
|
6,663 |
|
|
6,663 |
|
|||
Contacts
Justin J. File
858-898-0976
investor@meipharma.com
